P.134a Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update

Autor: Mendell, J., Sahenk, Z., Lehman, K., Lowes, L., Reash, N., Iammarino, M., Alfano, L., Lewis, S., Church, K., Shell, R., Potter, R., Griffin, D., Pozsgai, E., Hogan, M., Hu, L., Mason, S., Darton, E., Rodino-Klapac, L.
Zdroj: In Neuromuscular Disorders October 2022 32 Supplement 1:S102-S103
Databáze: ScienceDirect
Externí odkaz: